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GSK-3 betaeavy metals is a well-documented physiopathological mechanism in Alzheimer's
disease. An exacerbation of these abnormalities is best illustrated in the amyloid plaques in Alzheimer's
disease brain tissue, in which zinc reaches the enormous concentration of 1000 μM. Zinc in the plaques is
thought to originate from impaired glutamatergic neurons distributed in the associative cortex and limbic
structures of normal brain. Although the characteristics of zinc binding to Aβ and its role in promotion of Aβ
aggregation have been intensively studied, the contribution of zinc to the development of tau pathology
remains elusive. To further document the effect of zinc we have investigated the modiﬁcations of tau
phosphorylation, conformation and association to microtubules induced by zinc in clonal cell lines
expressing a human tau isoform. A bimodal dose dependent effect of zinc was observed. At 100 μM zinc
induced a tau dephosphorylation on the PHF-1 epitope, and at higher zinc concentrations induced the
appearance of the abnormal tau conformational epitope MC1 and reduced the electrophoretic mobility of
tau, known to be associated to increased tau phosphorylation. High zinc concentrations also increased
glycogen synthase kinase-3β (GSK-3β) phosphorylation on tyrosine 216, a phosphorylation associated with
increased activity of this tau kinase. Live imaging of tau-EGFP expressing cells demonstrated that high zinc
concentrations induced a release of tau from microtubules. These results suggest that zinc plays a signiﬁcant
role in the development of tau pathology associated to Alzheimer's disease.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionAlzheimer's disease (AD) is the most common type of dementia in
the elderly population. The late-onset sporadic form represents the vast
majority of the cases of AD, with occurrence of rare early-onset forms of
familial Alzheimer's disease caused by mutations in genes encoding for
the amyloidproteinprecursor (APP), andpresenilin 1 and2proteins. AD
is neuropathologically characterized by the presence of neuroﬁbrillary
tangles (composed of phosphorylated tau protein) and senile plaques
(containing extracellular deposits of Aβ amyloid surrounded by
dystrophic neurites). Increasing evidence suggests that aberrant brain
metal homeostasis is a detrimental process in AD. In particular, zinc
accumulation in the neocortex has been proved to be a prominent
feature of advanced AD [1] and is linked to brain amyloid Aβ peptide
accumulation [2,3], enhanced formation of reactive oxygen species [4,5]
and apoptosis [6]. Although physiological zinc concentration in brain
interstitial space does not exceed 0.5 μM, high levels of zinc, up to
1000 μM, can be reached within amyloid plaques in AD [7]. Such
pathological zinc concentrations might thus play a role in AD
pathogenesis. In agreement with this hypothesis the identiﬁcation offax: +322 555 6285.
ll rights reserved.S100A6, a protein that binds zincwith ahigher afﬁnity than calcium, in a
subset of astrocytes located in the amyloid plaque vicinity in both
sporadic AD and in transgenic mice developing Aβ deposits, suggests
that changes in expression levels of this protein might reﬂect some
compensatory mechanisms occurring during AD progression [8,9].
Physiologically, zinc is released during glutamatergic-zinc neurons
neurotransmission into the extracellular space, at the level of the
synaptic cleft where the zinc concentration reaches 300 μM [10]. The
zinc reuptake is achieved by non-speciﬁc neuronal presynaptic
membrane transporters [11] and concentrated via a speciﬁc zinc
transporter present in the synaptic glutamatergic vesicle membrane
(ZnT3). In AD, the abnormal metabolism of the amyloid precursor
protein (APP) leading to Aβ oligomers production and Aβ amyloid
deposits could impair the normal brain metal homeostasis by interfer-
ing with the physiological zinc reuptake [12]. Moreover, zinc has been
found to inhibit speciﬁcally the α-secretase cleavage of APP [13] and in
concentration above 300 nM rapidly precipitates human Aβ amyloid.
Zinc and Aβ amyloid acts synergistically to induce oxidative stress and
extra-mitochondrial production of reactive oxygen species [14]. Thus
good evidence indicates that endogenous zinc may contribute to the
formation of Aβ amyloid plaques, but less is known about a potential
effect of zinc on tau protein pathology although zinc has been reported
to affect tau translation and phosphorylation [15] and to be present in
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tion of tau decreases the binding of tau protein to microtubules and its
ability to stabilize them but also favours the formation of intracellular
aggregates of tau proteins, in the form of the neuronal-paired helical
ﬁlaments considered as another pathological key process in AD
pathology. Tau can be phosphorylated by several protein kinases
including the glycogen synthase kinase 3β (GSK-3β). GSK-3 is a
multifunctional proline-directed Ser/Thr kinase [17] found ubiquitously
in eukaryotes [18] and one of its isoforms, GSK-3β, is particularly
abundant in the central nervous system. GSK-3β has been shown to
phosphorylate tau onmany sites that are hyperphosphorylated in AD, in
vitro in mammalian transfected cells [19] and in transgenic animals. In
this study,wehave investigated the effect of zincon tauphosphorylation
and conformation and on tau binding to microtubules in cultured cells.
We observed that zinc had a bimodal effect on tau phosphorylation
depending on the zinc concentration, and induced GSK-3β activation
and tau release from microtubules. This study shows that tau
phosphorylation/conformation is modulated by zinc and suggests that
the abnormally high extracellular zinc concentration present in Aβ
amyloid plaques could play a role in neuronal tau pathology in AD.
2. Materials and methods
2.1. Cell culture and treatments
The 1C9 clonal CHO cells expressing stably the human 1N4R tau
isoform have been previously described [20]. For life-imaging of tau
distribution in cells treated or not with zinc, we generated a stable
clonal CHO cell line (102C5) expressing tau conjugated to EGFP by
cloning out wild-type CHO cells by limiting dilution in a selection
media containing G418, after transfection with the tau-EGFP plasmid
and a pSVtk neo plasmids using lipofectamine reagent (GIBCO BRL).
The tau plasmid expressing the human 2N3R tau isoform conjugated
to EGFP was previously described [21,22]. The cloned cell lines were
analysed by Western blotting for their ability to express tau proteins
and living cells examined under ultraviolet illumination to examine
tau distribution. Cells were grown in HAM F12medium supplemented
with 10% foetal bovine serum, 100 IU penicillin and 100 μg/ml
streptomycin and incubated at 37 °C with a 95% air/5% CO2 mixture.
Cultured cells were treated for 4 h with zinc by adding to the culture
medium zinc sulphate (Sigma, USA) from a stock solution (100 mM)
to obtain a ﬁnal range of concentrations of 100, 150, 250 and 500 μM.
Cultured cells were also treated with 10 μM of the speciﬁc glycogen
synthase kinase-3 inhibitor SB-216763 (Torcis, United Kingdom), in
absence or in presence of zinc.
2.2. Cell viability: 3-(4,5-dimethyl-thiazoyl-2-yl)2,5diphenyltetrazolium
bromide (MTT) assay
1C9 cells were cultured in 96-well plates, and after reaching
conﬂuency treated for 4 hwith 100–500 μMzinc sulphate. Twenty ﬁve
microliters of MTT solution (5 mg/ml) was then added to the media,
and the cells further incubated for 4 h at 37 °C. The MTT formazan
product was solubilized with an appropriate solution. Optical
densities were measured at 570 nm.
2.3. Antibodies
The rabbit polyclonal anti-tau antibody B19 was raised against
bovine tau proteins and reacted with human and rodent tau proteins
[23]. This antibody recognizes different tau isoforms both phosphory-
lated and unphosphorylated. The mouse monoclonal antibody PHF1
recognizes a speciﬁc epitope on the tau protein in a phosphorylation-
dependent manner, i.e. its reactivity with tau proteins is dependent of
the phosphorylation of Ser396/404 [24]. The monoclonal MC1
antibody recognizes an abnormal tau conformational epitope [25].The mouse monoclonal antibody TPK1 (Becton Dinkinson, USA) is
speciﬁc for GSK-3β and the rabbit polyclonal anti-GSKα/β (Biosource,
Belgium) is speciﬁc for active forms of GSK-3α phosphorylated on
tyrosine 279 and for GSK-3β phosphorylated on tyrosine 216. The
mouse monoclonal antibodies to α-tubulin (clone DM1-A), and to
β-actin (clone AC15) were purchased from Sigma (Bornem, Belgium).
2.4. Whole cell homogenate preparations
Cultured cells treated or not treated for 4 h with 100–500 μM zinc
sulphate were homogenized on ice in a buffer (Tris 50 mM, EDTA
10 mM, NaCl 100 mM, pH 7.4) containing protease and phosphatase
inhibitors (1 mM phenylmethylsulphonyl-ﬂuoride (PMSF), leupeptin
25 μg/ml, pepstatin 25 μg/ml, Na3VO4 1 mM, NaF 20 mM). The
amount of proteins in homogenates was estimated with the Bradford
method (Bio-Rad reagent, USA).
2.5. Western blotting
Homogenates of cultured 1C9 cells, treated or not for 4 h with
100–500 μM of zinc sulphate were analysed by sodium dodecyl
sulphate-polyacrylamide (10%) gel electrophoresis (SDS-PAGE). The
extractswere ﬁrstmixedwith a sample buffer (10mMTris–HCl, pH6.8,
1.5% SDS, 0.6% DTTand 6% (v/v) glycerol) and heated at 95 °C for 2min.
After separation, proteins were electrophoretically transferred to
nitrocellulose membranes. Nitrocellulose membranes were blocked
in non-fat milk (10% (w/v) in TBS) for 1 h at room temperature and
incubated with the primary antibody overnight, followed by either
anti-mouse or anti-rabbit immunoglobulins conjugated to biotin,
followed by streptavidin conjugated to alkaline phosphatase. Mem-
branes were ﬁnally incubated in the developing buffer (Tris 0.1M, NaCl
0.1 M, MgCl2 0.05 M, pH 9.5) containing nitro blue tetrazolium and 5-
bromo-4-chloro-3-indolyl phosphate. The densitometry analysis of
westernblotswasperformedwith the Image J 1.34program(NIH,USA).
2.6. Immunocytochemistry
Cultured 1C9 cells treated or not for 4 h with 100–500 μM zinc
sulphate were rinsed in TBS (0.01 M Tris, 0.15 M NaCl, pH 7.4) buffer
and ﬁxed for 10min in 4% (w/v) paraformaldehyde in 0.1Mphosphate
buffer, pH 7.6. Tau immunohistochemical labelling was performed
using the avidin–biotin-peroxidase complex (ABC) method. Brieﬂy,
ﬁxed cells were incubated for 1 h at room temperature with the
blocking solution diluted in TBS (5% (v/v) of goat or sheep normal
serum (depending on the origin of the secondary antibody). After an
overnight incubation with the anti-tau antibodies (B19 1/3000; PHF1
1/50.000, the 1C9 cells were sequentially incubated with the
appropriate secondary antibodies reagents (Vector Laboratories, The
Netherlands) conjugated to biotin (1:100) followed by the avidin–
biotinperoxidase complex (Vector Laboratories, TheNetherlands). The
peroxidase activity was revealed using diaminobenzidine as chromo-
gen. Immunoﬂuorescence using anti-tau antibodies was also per-
formed on 1C9 cells grown on coverslips. The coverslips were rinsed
with Tris-buffered saline (TBS) and ﬁxedwith 4% of paraformaldehyde
in TBS, permeabilized with 0.15% Triton X-100 in PBS for 10 min and
washed three timeswith TBS. The ﬁxed cells were preincubated for 1 h
at room temperature with 1:30 normal serum in TBS. Incubation with
the anti-tau antibodies (B19 and PHF1 and MC1) was performed
overnight. After washing in TBS, the cells were incubated 1 h in the
darkwith theﬂuorescein-labelled secondary antibody at 1:30 dilution.
Cells were again washed three times in PBS for 10 min, rapidly rinsed
with distilled water, and mounted with Mowiol mounting medium
(Calbiochem, USA) solution containing 100 mg/ml DABCO reagent
(Sigma, USA). Cells were observed under a Zeiss Axiovert ﬂuorescence
microscope equipped with a Laser-Scanning Confocal Microscope
(MRC 1000, BioRad) using an argon–krypton laser.
Fig.1. Characterisation of tau expression inCHOcell lines used in this study. Homogenates
of wild-type CHO cells (lane 1), clonal 102C5 cells (lane 2) and clonal 1C9 cells (lane 3)
were analysedbywestern blottingwith theB19 pan-tau antibody.Wild-type CHOcells do
not express tau proteins. 1C9 cells express a 1N4R tau isoform and 102C5 cells a higher
molecular weight 2N3R tau isoform conjugated to EGFP. The number on the left refers to
the position of a molecular weight marker (58 kDa: catalase).
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For measurement of intracellular zinc, 1C9 cells were ﬁrst washed
twice with Hepes buffer (10 mM Hepes, 150 mM NaCl, 5 mM KCl,
1 mM MgCl2, 5 mM glucose, 4 mM glutamine, and 1.8 mM CaCl2,Fig. 2. Measurement of zinc accumulation by spectroﬂuorometry experiments performed o
presence of 250 μM zinc sulphate (ﬁrst arrow on the time axis) and a ratio measurement (R=
The ratio curve increased linearly as a function of the incubation time to reach 120% of initial
300 s incubation period, ionomycine was added to the culture medium and ratio values (
Ionomycine induced an important increase in zinc entry, characterized on the graph by a
measuring ﬂuorescence emission of FuraZin loaded cells. Measurements were performed at 0
is present in resting cell, no recording was performed at time 0 h. Data are given as ratio of e
from 2 independent experiments (mean±SEM). Zinc accumulated steadily in cells duringpH=7.4) and then loaded with 2 μM FuraZin acetoxymethyl ester (a
ﬂuorescent probe for zinc) (Molecular Probes, USA) in Hepes buffer
for 30 min at 37°C. After loading with this ﬂuorescent probe, the cells
were incubated in Hepes buffer for 15 min to allow complete de-
esteriﬁcation of the dye. Coverslips with loaded cells were mounted in
a 1 ml thermostated (37 °C) open chamber placed on an Olympus
inverted microscope as previously described [26]. Zinc sulphate was
added to the chamber in a volume of 100 μl Hepes buffer. Changes in
FuraZin ﬂuorescence in individual cells were measured by ratio
ﬂuorometry using a camera-based TillVision imaging system (Till
Photonics, Gräfelﬁng, Germany). Fluorescence signals emitted at
550 nm after excitation at 340 and 380 nm were measured, and
ratio values were calculated.
2.8. Live-imaging observation of tau-EGFP expressing cells
The effect of treatment with 250 μM zinc sulphate on the
microtubule network of cultured cells was analysed by time-lapse
imaging of 102C5 cells (expressing an 2N3R human tau-EGFP
isoform). Cultured 102C5 cells were incubated at 37 °C with a 5%
CO2/95% air mixture in a thermostatic chamber placed on the stage ofn 1C9 cultured cells. (A) Cells were loaded with FuraZin and incubated during 300 s in
F340 nm/F380 nm) was performed every second and plotted in a time vs. ratio graph.
value, indicating moderate entry of zinc during this incubation period. At the end of the
F340 nm/F380 nm) were measured for another 200 s and plotted in the same graph.
slope increase. (B) The increase in Zn2+ absorption by 1C9 cells was determined by
.5, 1, 2, 3 and 4 h after adding 250 μM zinc sulphate (ﬁnal concentration). Since no Zn2+
mitted light at 340 nm and 380 nm excitation. Values are averaged from at least 11 cells
the 4 h incubation period.
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Axiocam MR black and white camera. Digital images were auto-
matically captured every 10 min during a 4 hour period using the
Axiovision software (Zeiss, Germany).
3. Results
3.1. Tau expression in cell lines
Tau expression in the cell lines used in this study was analysed by
western blotting. As reported previously, wild-type CHO cells do not
express tau proteins whereas clonal 1C9 cells expressing a single tau
isoform show a major species with an apparent molecular weight of
60 kDa (Fig.1, lane 3) [20]. The clonal 102C5 cells express a tau isoform
conjugated with EGFP and with an apparent higher molecular weight
(Fig. 1, lane 2). Life 102C5 cells examined under ultraviolet illumina-
tion showed a ﬂuorescent microtubule network, due to the binding of
tau-EGFP to microtubules (Fig. 8).
3.2. Cell viability
As estimated by the MTT tests, zinc sulphate treatment did not
induce any signiﬁcant toxicity in human tau CHO transfected cells
using up to 500 μM concentration during a four-hour-time incubation
(data not shown).Fig. 3. Photomicrographs of immunocytochemical labelling (no counterstaining) with the ph
sulphate for 4h (B–Dand F). (A and B) Control 1C9 cells showed amoderate cytoplasmic PHF-1
in PHF-1 immunoreactivity (B). (C and D) On the contrary, increased PHF-1 labelling was ob
Under this latter condition a nuclear labelling for tauwas also observed. (E and F) Immunoﬂuo
1C9 cells (E) showed a reticular staining throughout the cell whereas cells treated with 2503.3. Spectroﬂuorometry conﬁrms zinc entry into cultured cells
Spectroﬂuorometry experiments were carried out to ensure that zinc
penetrates and accumulates into the cultured cells. To this end, two
experiments were performed on 1C9 cells. In the ﬁrst one cells loaded
with FuraZin were incubated with 250 μM zinc sulphate. The
340 nm/380 nm ratio increased linearly as a function of the incubation
time to reach 120% of the initial value after 300 s of incubation (Fig. 2A),
indicating a moderate entry of zinc into cells even during this short
period. To conﬁrm that the increase in ratio values was due to zinc entry,
ionomycine was added at the end of the incubation period of 300 s.
Measurements of ratio values showed an important increase in zinc
entry, characterized on the graph by a steeper slope (Fig. 2A). In a second
experiment, cells were incubated for 0 h, 0.5 h, 1 h, 2 h, 3 h and 4 h in a
mediumcontaining250 μMzinc. Cellswere thenwashedand loadedwith
2 μM Furazin. Five snapshots were taken at both excitation wavelengths
(340 nm and 380 nm) and averaged ratios values calculated. The ratio
value started at 0.525 and reached a value of 0.650 after 4 h (Fig. 2B),
conﬁrming zinc steadily accumulation into cells on longer period,
comparable to zinc entryobservedona shorter periodwithan ionophore.
3.4. Zinc induces modiﬁcations of tau expression and phosphorylation
In order to determine the effect of zinc on tau expression and
phosphorylation, 1C9 cells were treated during 4 h with increasingosphotau antibody PHF-1 on control 1C9 cells (A and E) and 1C9 cells treated with zinc
labelling,whereas 1C9 cells treated for 4hwith 100 μMzinc sulphate showed a decrease
served when the cells were incubated with 150 μM (C) and 250 μM of zinc sulphate (D).
rescence pictures of the PHF-1 labelling obtainedwith a confocal microscope. Untreated
μM of zinc sulphate (F) showed an increased labelling. Scale bar: 25 μM.
Fig. 4. Effect of zinc sulphate on tau expression and PHF-1 phosphotau immunoreactivity. (A) Immunoblotting of total cell lysates (100 μg/lane) from 1C9 cells treated or not with
different zinc sulphate concentration and probed with the B19 antibody recognizing both phosphorylated and unphosphorylated tau (panel A1) or with the phosphorylation-
dependent monoclonal tau antibody PHF-1 (panel A2). 1C9 cells exposed to 250 and 500 μM zinc sulphate showed an apparent increase of tau expression and a reduced
electrophoretic mobility when probedwith the B19 tau antibody (panel A1). 1C9 cells exposed to 100 μMzinc sulphate and probed with the PHF-1 tau antibody showed a decrease in
tau phosphorylation (panel A2—100 μM). In contrast, incubationwith higher zinc sulphate concentrations led to an apparent increase in PHF-1 tau immunoreactivity. The number on
the left refers to the position of a molecular weight marker (58 kDa: catalase). (B) Densitometry quantiﬁcations performed on eight independent experiments. Decreased tau
expression and PHF-1 phosphotau was statistically signiﬁcant for 100 μM zinc (panel B1) and increased tau expression and PHF-1 phosphotau was signiﬁcant for 250 μM (panel B2)
(as means±SEM, relative to controls). Calculated PHF-1/total tau (B19) ratios were statistically signiﬁcant for 100 μMzinc sulphate (panel B3). ⁎pb0.05; ⁎⁎pb0.01. ANOVAwith post
tests for comparison with control cells.
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and immunobloting with tau antibodies. In the absence of zinc sul-
phate, a weak cytoplasmic immunostaining by the phosphorylation-Fig. 5. Effect of zinc sulphate on the appearance of the abnormal MC1 tau conformational
conformationalMC1 tauantibody (panelA1) or an anti-actin antibody (panelA2).AMC1 immun
zinc sulphate concentration. In contrast, at 150 μM or higher zinc sulphate concentrations, a M
position of themolecular weightmarker (58 kDa: catalase). (B) Densitometry quantiﬁcation ofdependent anti-tau antibody PHF1 could be observed (Fig. 3A —
Control). PHF1 immunolabelling was clearly decreased when the cells
were incubated 4 h with 100 μM zinc sulphate (Fig. 3B—100 μM). Inepitope. (A) Immunoblotting of total cell lysates (100 μg/lane) from 1C9 cells with the
oreactivitywas absentwhen1C9 cellswere incubated in the absenceorwith low (100 μM)
C1-positive tau species was observed. The number on the left of the panel indicates the
theMC1/actin ratios, that increased sharply for zinc sulphate concentrations above 100 μM.
Fig. 6. Effect of zinc sulphate on GSK-3β phosphorylation. (A) Immunoblotting of 1C9 cell lysates with the anti-GSK 3β/α [pY216] antibody (panel A1) or the total anti-GSK-3β
antibody TPK1 (panel A2). Treatment with 250 and 500 μM of zinc sulphate increased the level of GSK-3β phosphorylated on tyrosine 216 [pY216] whereas the phosphorylation of
GSK-3α [pY279] and the level of total GSK-3β (TPK1) were not affected. (B) Densitometry quantiﬁcation of GSK-3β [pY216]/total GSK-3β ratios following treatment with different
zinc concentration from three independents experiments (expressed as mean±SEM, relative to controls). Numbers on the left of panels A1 and A2 indicate the position of GSK-3α
(51 kDa) and GSK-3β (47 kDa). ⁎pb0.05, compared with controls by one sample t test.
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an increase in PHF1 immunolabelling (Fig. 3C and D). A nuclear PHF-1
immunolabelling of ﬁxed 1C9 cells was also observed after incubation
with 250 μM zinc (Fig. 3D). Immunoﬂuorescence observation with
confocal microscopy conﬁrmed the increased PHF-1 labelling in 1C9
cells in the presence of 250 μM zinc sulphate (Fig. 3E and F). These
modiﬁcations in PHF-1 immunolabelling of 1C9 cells exposed to zinc
sulphate were conﬁrmed by immunoblotting experiments. Homo-Fig. 7. Effect of the GSK-3β inhibitor SB-216763 on PHF-1 tau immunoreactivity and tau electrop
observed in 1C9 cells incubated with 250 μM zinc sulphate (A) and addition of 10 μM of
Immunoblotting of 1C9 cell lysates with the B19 total tau antibody (panel C1) and the PHF-
immunoreactivity is present in cells treated with zinc (lanes 2) or with zinc and SB-216763 (
experiments. A signiﬁcant decrease is present in cells treatedwith SB-216763 or to a lesser exten
control cells.genates of 1C9 cells exposed to 100 μM zinc sulphate showed a
decrease in PHF-1 tau immunoreactivity (Fig. 4A, panel A2, lane 2).
Incubationwith higher zinc sulphate concentrations led to an increase
in PHF-1 immunoreactivity (Fig. 4A, panel A2, lanes 4 and 6).
Incubation with 250 μM and 500 μM zinc sulphate also decreased the
electrophoretic mobility of tau (Fig. 4A, panel A1, lanes 4 and 6), a
reported electrophoretic behaviour associated to selected changes in
tau phosphorylation [27,28]. The total level of tau estimated with thehoreticmobility in presence of 250 μMzinc sulphate. (A and B) A strong PHF-1 labelling is
SB-216763 led to a reduction of PHF-1 immunoreactivity in zinc-treated cells (B). (C)
1 tau antibody (panel C2). A reduction in electrophoretic mobility of tau and of PHF-1
lanes 4). (D) Densitometry quantiﬁcation of PHF-1/B19 ratios from three independents
twith zinc and SB-216763. ⁎pb0.05; ⁎⁎pb0.01. ANOVAwith post tests for comparisonwith
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observed to be increased in 1C9 cells treated with 250 and 500 μM
zinc sulphate (Fig. 4A, panel A1). The densitometry quantiﬁcation of
total tau (B19) (Fig. 4B, panel B1) and of PHF-1 phosphotau (Fig. 4B,
panel B2) conﬁrmed the decrease of PHF-1 immunoreactivity at
100 μM zinc sulphate and the increase of tau expression and of PHF-1
immunoreactivity after incubationwith 250 and 500 μMzinc sulphate.
The calculated PHF1/B19 densitometry ratios (Fig. 4B, panel B3)
indicated a signiﬁcant decrease of this ratio for 100 μM zinc sulphate
but these ratioswere not signiﬁcantly different for higher zinc sulphate
concentrations, despite a trend for increased values.
3.5. Zinc induces the appearance of the MC1 tau conformational epitope
By immunoblotting we then examined the effect of zinc sulphate
on the appearance of modiﬁed conformational epitopes on tau, using
the conformational MC1 tau antibody that recognizes a discontinuous
epitope on the tau molecule and considered as one of the earliest
pathological alterations of tau in AD. MC1 immunolabelling was
undetectable in untreated 1C9 cells or in cells treated with 100 μM
zinc sulphate (Fig. 5A, panel A1, lanes 1 and 2), but an obvious MC1
positive tau species was detected at 150 μM or at higher zinc sulphate
concentrations (Fig. 5, panel A1, lanes 3 to 6).
3.6. Zinc induces GSK-3β phosphorylation on tyrosine 216
Immunoblots of total cell lysates from 1C9 cells exposed to
different extracellular zinc sulphate concentrations and probed withFig. 8. Effect of zinc on tau association to microtubules studied by time-lapse imaging in life
time-lapse observation (t=0′) (A), cells expressing tau conjugated to EGFP show a ﬂuorescen
Zinc treatment led to a progressive disappearance of the microtubule network that was rep
ﬂuorescence throughout the cell cytoplasm (B). (C and D) Control untreated cells. Time-laps
end (D) of the time-lapse observation. Scale bar: 15 μM.the anti-GSK 3β/α [pY216] antibody showed an increased level of
GSK-3β phosphorylated on tyrosine 216 [pY216] for the highest zinc
concentration (250 and 500 μM) (Fig. 6A, panel A1, lanes 3 and 4).
Phosphorylation of GSK-3α [pY279] (Fig. 6A, panel A1) and expres-
sion of total GSK-3β (estimated with the TPK1 antibody) (Fig. 6A,
panel A2) were not affected by zinc treatments. The calculated GSK-
3β [pY216]/total GSK-3β densitometry ratios are shown in Fig. 6B
and indicate a signiﬁcant increase for the highest zinc sulphate
concentration.
The effect of SB-216763, a speciﬁc inhibitor of GSK-3β, was
investigated to determine if GSK-3β was involved in modiﬁcations
in phosphorylation and electrophoretic mobility of tau in cells treated
by higher zinc sulphate concentrations. Treatment with SB-216673
decreased PHF-1 immunoreactivity of cells treated with zinc (Fig. 7A
versus B). By immunoblotting tau phosphorylation detected by the
PHF1 antibody in the absence of zinc was strongly reduced by
treatment with SB-216763 (Fig. 7C, panel C2, lane 1 vs. lane 3). In
presence of zinc, PHF-1 tau immunoreactivity was also reduced by
treatment with SB-216763 (Fig. 7C, panel C2, lane 2 vs. lane 4) and
reduced tau electrophoretic mobility induced by zinc was almost not
affected by SB-216763 (Fig. 7C, panel C1, lane 2 vs. lane 4). The
calculated PHF-1/total tau (B19) densitometry ratios of three
independent experiments are shown in Fig. 7D and indicate a
signiﬁcant decrease of PHF-1 tau immunoreactivity in cells treated
with SB-216763, both in absence or presence of zinc. These results
thus suggest that GSK-3β maintains tau PHF-1 immunoreactivity in
cells treated with zinc but is not responsible for the reduced
electrophoretic mobility of tau in these cells.clonal 102C5 cells. (A and B) Cells treated with 250 μM zinc sulphate. At the start of the
t microtubule network, due to the association of the tau-EGFP proteins to microtubules.
laced after 4 h (t=240′, last record of the time-lapse observation) by an uniform tau
e imaging showed the persistence of the microtubule network from the start (C) to the
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zinc-treated cells
To further document the change in cellular distribution of tau
induced by zinc, the effect of 250 μM zinc sulphate was analysed by
time-lapse imaging on living CHO cells expressing a human tau-EGFP
isoform (Clone 102C5). Before zinc sulphate addition, cells showed a
ﬂuorescent ﬁbrillar pattern corresponding to the microtubule net-
work, due to the association of the tau-EGFP proteins to microtubules
(Fig. 8A). The addition of 250 μM zinc led progressively in 4 h to the
disappearance of the ﬂuorescent microtubule network that was
replaced by an uniform tau ﬂuorescence throughout the cell
(Fig. 8B). 102C5 cells untreated with zinc were examined in parallel
by time-lapse imaging. These untreated cells did not show a
disappearance of the ﬂuorescencemicrotubular network after a period
of 4 h of time-lapse imaging (Fig. 8C and D). This ﬂuorescence pattern
suggested that tau-EGFP proteins were detached from microtubules
and/or that microtubules were depolymerised in presence of zinc.
3.8. The microtubule network is still present in zinc-treated cells
To further document the integrity of the microtubule network in
zinc-treated cells, 102C5 cells were immunolabelled with the anti-
α-tubulin antibody after treatment with zinc sulphate. The micro-
tubule network present in untreated cells (Fig. 9A) was still present in
cells treated for 4 hwith 150 (Fig. 9B) or 250 μM(Fig. 9C) zinc sulphate.
4. Discussion
Elevated intracellular free zinc (i.e. zinc ions not complexed to
intracellular proteins) is neurotoxic and its accumulation may
contribute to neuronal injury in several diseases, including in
neurodegenerative conditions such as Alzheimer's disease. Aberrant
zinc metal homeostasis has been reported in the brains of AD patients
and this metal could contribute to the development of the lesions [1].
Although much evidence indicates that zinc enhances the develop-
ment of amyloid pathology in AD [12,29,30], the effect of zinc on the
development of tau pathology has been studied only in few studies
[15]. The present study shows that tau phosphorylation and
conformation is modulated by zinc in a concentration dependent
manner in a cellularmodel. The intracellular concentration of free zinc
is normally low and elevation of intracellular zinc results from entry
through calcium permeable channels [31]. Our spectroﬂuometric
analysis conﬁrmed that zinc ions added extracellularly entered and
accumulated into cultured cells in our experimental conditions.
Interestingly, we observed a bimodal evolution of tau phospho-
rylation and an abnormal epitope conformation when using increa-Fig. 9. Effect of zinc sulphate on the microtubule network in 102C5 cells. Immunolabelling w
(B) or 500 μM (C) zinc sulphate. The microtubule network is still present in zinc-treated cesing concentration of zinc sulphate. At the lowest zinc concentration
of 100 μM, tau phosphorylation at Ser396/404, identiﬁed by the PHF-1
antibody, decreased signiﬁcantly. Tau dephosphorylation induced by
zinc could result from either activation of protein phosphatases or
inhibition of protein kinases e.g. zinc has been reported to inhibit
GSK-3β in vitro in an uncompetitive manner, with an almost complete
inhibition at 100 μM [32], suggesting that tau dephosphorylation
observed in these cells might bemediated by direct GSK-3β inhibition.
For zinc concentration higher than 100 μMwe observed an increase of
PHF-1 immunoreactivity but that probably reﬂected a parallel
increase in tau expression. This effect was also observed in a previous
study [33], and attributed to an increased activity of a 70 kDa
ribosomal protein S6 kinase regulating protein translation. We also
observed that high concentrations of zinc actually increased phos-
phorylation of GSK-3β on Tyr216, a phosphorylation event associated
to increased activity of GSK-3β [34]. GSK-3β has been observed to be
associated to neuronal lesion in AD [34] and the level of GSK-3β
phosphorylated onTyr 216 (an active form of the enzyme) increases in
AD [35]. In addition, for zinc concentration above 100 μM,we detected
a conformational change in tau by using the conformational MC1
antibody, which recognizes a discontinuous epitope along the tau
molecule [25]. Interestingly, the appearance of the MCI epitope is
considered as one of the earliest pathological alterations of tau in AD
[25]. Another indication of increased tau phosphorylation and
conformational change for zinc concentrations above 100 μM was its
reduced electrophoretic mobility, a reported electrophoretic beha-
viour associated to increased tau phosphorylation [27]. This increased
tau phosphorylation could be directed at other sites than the PHF-1
site (Ser 396/404), e.g. phosphorylation at Ser202/Thr205, known to
reduce electrophoretic mobility of tau [28]. This reduced electro-
phoretic mobility induced by zinc was not affected by co-treatment
with a GSK-3β inhibitor, suggesting that GSK-3β was not primarily
involved in the zinc-induced reduced electrophoretic mobility of tau.
The presence of a nuclear tau immunoreactivity in ﬁxed cells,
although reminiscent of previous observations reporting the presence
of neuronal nuclear tau in AD brains [36], should be interpreted with
caution since it was not observed by life imaging of cells expressing
tau-EGFP, and we cannot exclude that it represents a redistribution of
tau during ﬁxation [37]. By time-lapse imaging using cells expressing
tau-EGFP we observed that 250 μM of zinc causes also an intracellular
redistribution of tau protein with the disappearance of its association
to themicrotubule network, the latter being still present in these zinc-
treated cells. Binding of tau to microtubules is regulated through
phosphorylation and increased GSK-3β activity reduces the associa-
tion of tau with microtubules [38,39]. In a previous study [33], an
increase of tau phosphorylation was reported when SH-SY5Y cells
were treated with a single concentration of 100 μM of zinc in serum-ith an anti-α tubulin antibody. Cells were untreated (A), or treated for 4 h with 250 μM
lls. Scale bar: 25 μm.
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different cell type might explain these differences with the results
reported in this study. The present observations investigating the
effect of increasing zinc concentrations on tau phosphorylation, tau
conformation, and association to microtubules should be extended in
further studies on neuronal cells. The cell lines used in this study are
however an adequate cellular model to evaluate at ﬁrst the effect of
zinc on tau phosphorylation and its association to microtubules, since
these clonal cell lines express tau at a moderate level (by comparison
with transiently transfected cells) and tau in these cells is physiolo-
gically associated to microtubules. In addition, due to the ﬂat aspect of
these cells, the microtubule network is quite spread, allowing an
easier estimation of modiﬁcations of this network in experimental
conditions.
Thus our results suggest that high concentration of zinc might
induce increased tau phosphorylation and conformational modiﬁca-
tions of tau, typical of early changes in neurons developing neuroﬁ-
brillary tangles. Interestingly, zinc is highly concentrated in brain
areas or in projections to these brain areas that are more selectively
affected by the neuroﬁbrillary pathology. The highest chelatable zinc
is essentially restricted to the synaptic vesicles of a sub-population of
glutamatergic neurons of the dentate gyrus generating mossy ﬁbre
boutons in the hippocampus (which store the highest levels of
vesicular zinc), and neurons in amygdala nuclei, enthorhinal and
pyriform cortices and in associative neocortex. Efferent zinc contai-
ning ﬁbres from these regions are in turn directed almost exclusively
to cerebral cortex and limbic targets [40]. The hippocampal formation,
the perirhinal cortex and the subiculum are the major points of
convergence of zinc-containing neurons and thus heavily innervated
by zinc-containing buttons and strikingly those regions are severely
affected in AD. On the contrary, zinc-containing neurons are generally
not found in the spinal cord and in the cerebellum and the latter areas
are devoid of neuroﬁbrillary lesions in AD. At the synaptic level zinc is
released during glutamatergic neurotransmission and participate to
control of post-synaptic proteins like the NMDA and GABA receptors
[41]. Ionic zinc is restricted and concentrated into the glutamatergic
synaptic vesicle by the ZnT3 transporters residing on the synaptic
vesicle membranes of zinc-containing neurons [42]. Accordingly, ZnT3
mRNA expression was observed to be high in the same regions as
those where ionic zinc is found. Zinc is strongly suspected to play a
role in the development or the enhancement of amyloid deposits. In
AD, zinc ions are enriched in the neocortical areas, and even further
concentrated into amyloid deposits [3] suggesting that interactions
between Aβ and zinc play a role in AD pathogenesis [2,5,14]. Zinc is
also found in high concentration in the plaques in the brains of
transgenic APP mouse models of AD [30]. We suggest that the
abnormally high zinc concentration in amyloid plaques could also play
a role in the tau pathology observed in AD. Amyloid plaques are
surrounded by abnormal dystrophic neurites and high concentrations
of zinc in these neurites as observed by Timm's staining method for
zinc [43], could explain the repeated observations of increased tau
phosphorylation in dystrophic neurites associated to amyloid deposits
in plaques, both in AD [44] and in transgenic APP mice models [45].
In conclusion, this study shows that tau phosphorylation and
conformation is modulated by zinc and we suggest that the abnormal
extracellular zinc concentration present in Aβ amyloid plaques could
play a role in neuronal tau pathology in AD and could explain the
preferential development of tau pathology in brain areas rich in zinc in
this disease.
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